Joanne S. Wilson

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Implementing psychology-based empathetic refutational interview training to support vaccine confident conversations for health workers.

Implementing psychology-based empathetic refutational interview training to support vaccine confident conversations for health workers.

Journal: Public health

Published: August 13, 2025

Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase.

Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase.

Journal: Drug metabolism and disposition: the biological fate of chemicals

Published: February 16, 2025

Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations.

Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations.

Journal: Journal of medicinal chemistry

Published: January 27, 2025

Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.

Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.

Journal: Molecular cancer therapeutics

Published: January 21, 2025

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.

Journal: Communications biology

Published: January 17, 2024

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.

Journal: Cancer research communications

Published: October 25, 2022

Good medicines management: From describing problems to a vision for change.

Good medicines management: From describing problems to a vision for change.

Journal: Palliative medicine

Published: February 14, 2022

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 10, 2022

Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution.

Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution.

Journal: Theranostics

Published: October 12, 2021

The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.

The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.

Journal: Molecular cancer therapeutics

Published: May 10, 2021

Covid-19 communication: planning ahead to help inpatients when key contacts can't be present.

Covid-19 communication: planning ahead to help inpatients when key contacts can't be present.

Journal: BMJ (Clinical research ed.)

Published: September 19, 2020

ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.

ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.

Journal: Science translational medicine

Published: June 30, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026